1169 related articles for article (PubMed ID: 20399324)
21. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
[TBL] [Abstract][Full Text] [Related]
22. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
[TBL] [Abstract][Full Text] [Related]
23. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
24. [Surveillance of patients with Barrett's esophagus].
Endlicher E; Knüchel R; Messmann H
Z Gastroenterol; 2001 Aug; 39(8):593-600. PubMed ID: 11558064
[TBL] [Abstract][Full Text] [Related]
25. Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma.
Grant KS; DeMeester SR; Kreger V; Oh D; Hagen JA; Chandrasoma P; DeMeester TR
J Thorac Cardiovasc Surg; 2013 Jul; 146(1):31-7. PubMed ID: 23312980
[TBL] [Abstract][Full Text] [Related]
26. Low-grade dysplasia in Barrett's esophagus has a high risk of progression.
Lim CH; Treanor D; Dixon MF; Axon AT
Endoscopy; 2007 Jul; 39(7):581-7. PubMed ID: 17611911
[TBL] [Abstract][Full Text] [Related]
27. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
Provenzale D; Schmitt C; Wong JB
Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
[TBL] [Abstract][Full Text] [Related]
29. Outcome of endoscopy surveillance for Barrett's oesophagus.
Bright T; Schloithe A; Bull JA; Fraser RJ; Bampton P; Watson DI
ANZ J Surg; 2009 Nov; 79(11):812-6. PubMed ID: 20078532
[TBL] [Abstract][Full Text] [Related]
30. A surveillance programme for Barrett's oesophagus in a UK general hospital.
Olithselvan A; Gorard DA; McIntyre AS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
[TBL] [Abstract][Full Text] [Related]
31. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.
Bytzer P; Christensen PB; Damkier P; Vinding K; Seersholm N
Am J Gastroenterol; 1999 Jan; 94(1):86-91. PubMed ID: 9934736
[TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.
Weston AP; Badr AS; Topalovski M; Cherian R; Dixon A; Hassanein RS
Am J Gastroenterol; 2000 Feb; 95(2):387-94. PubMed ID: 10685740
[TBL] [Abstract][Full Text] [Related]
33. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
34. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
35. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia.
Reid BJ; Blount PL; Feng Z; Levine DS
Am J Gastroenterol; 2000 Nov; 95(11):3089-96. PubMed ID: 11095322
[TBL] [Abstract][Full Text] [Related]
36. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.
Cameron AJ; Carpenter HA
Am J Gastroenterol; 1997 Apr; 92(4):586-91. PubMed ID: 9128304
[TBL] [Abstract][Full Text] [Related]
37. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
38. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
O'Connor JB; Falk GW; Richter JE
Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
[TBL] [Abstract][Full Text] [Related]
39. Management of Barrett's esophagus free of dysplasia.
DeMeester SR
Semin Thorac Cardiovasc Surg; 1997 Jul; 9(3):279-84. PubMed ID: 9263346
[TBL] [Abstract][Full Text] [Related]
40. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer.
Fountoulakis A; Zafirellis KD; Dolan K; Dexter SP; Martin IG; Sue-Ling HM
Br J Surg; 2004 Aug; 91(8):997-1003. PubMed ID: 15286961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
